126 related articles for article (PubMed ID: 21985806)
1. Genetic polymorphism of drug refractory epilepsy.
Kesavan R; Kukreti R; Adithan C
Indian J Med Res; 2011 Sep; 134(3):253-5. PubMed ID: 21985806
[No Abstract] [Full Text] [Related]
2. Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Lakhan R; Kumari R; Singh K; Kalita J; Misra UK; Mittal B
Indian J Med Res; 2011 Sep; 134(3):295-301. PubMed ID: 21985811
[TBL] [Abstract][Full Text] [Related]
3. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
4. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
6. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of pharmacogenetics on the treatment of epilepsy.
Löscher W; Klotz U; Zimprich F; Schmidt D
Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
[TBL] [Abstract][Full Text] [Related]
8. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
[TBL] [Abstract][Full Text] [Related]
9. Distribution of CYP2C polymorphisms in an Amerindian population of Brazil.
Vargens DD; Petzl-Erler ML; Suarez-Kurtz G
Basic Clin Pharmacol Toxicol; 2012 Apr; 110(4):396-400. PubMed ID: 21977947
[No Abstract] [Full Text] [Related]
10. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
11. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics: reality or fiction? Or are we there yet?
Lopes-Cendes I; Guerreiro CA
Arq Neuropsiquiatr; 2011 Apr; 69(2A):151-2. PubMed ID: 21537550
[No Abstract] [Full Text] [Related]
13. [Genetic polymorphism of CYP-450 in drug development].
Nonen S; Azuma J
Nihon Yakurigaku Zasshi; 2009 Oct; 134(4):212-5. PubMed ID: 19828926
[No Abstract] [Full Text] [Related]
14. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).
Pachkoria K; Lucena MI; Ruiz-Cabello F; Crespo E; Cabello MR; Andrade RJ;
Br J Pharmacol; 2007 Mar; 150(6):808-15. PubMed ID: 17279092
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
16. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.
Rosemary J; Adithan C
Curr Clin Pharmacol; 2007 Jan; 2(1):93-109. PubMed ID: 18690857
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array.
Pickering JW; McMillin GA; Gedge F; Hill HR; Lyon E
Am J Pharmacogenomics; 2004; 4(3):199-207. PubMed ID: 15174901
[TBL] [Abstract][Full Text] [Related]
18. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.
Hirota T; Eguchi S; Ieiri I
Drug Metab Pharmacokinet; 2013; 28(1):28-37. PubMed ID: 23165865
[TBL] [Abstract][Full Text] [Related]
19. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.
Kim SH; Kim SH; Yoon HJ; Shin DH; Park SS; Kim YS; Park JS; Jee YK
Eur J Clin Pharmacol; 2011 Feb; 67(2):121-7. PubMed ID: 20941486
[TBL] [Abstract][Full Text] [Related]
20. Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response.
Nastasi-Catanese JA; Padilla-Gutiérrez JR; Valle Y; Ortega-Gutiérrez F; Gallegos-Arreola MP; Figuera LE
Genet Mol Res; 2013 Oct; 12(4):4413-21. PubMed ID: 24222221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
